Droxidopa is a medication used to treat symptomatic orthostatic hypotension (OH) [1]. This condition causes a significant drop in blood pressure upon standing, leading to dizziness and lightheadedness [1].
How does droxidopa work?
Droxidopa functions as a prodrug, meaning it is converted in the body into norepinephrine, a natural neurotransmitter [2]. Norepinephrine helps to constrict blood vessels, which in turn helps to raise blood pressure and alleviate the symptoms of orthostatic hypotension [2].
When did droxidopa become available?
Droxidopa, marketed as Northera, was approved by the U.S. Food and Drug Administration (FDA) in 2014 [3].
What are the potential side effects of droxidopa?
Common side effects reported with droxidopa include headache, dizziness, nausea, vomiting, and high blood pressure [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider [1].
How does droxidopa compare to other treatments for orthostatic hypotension?
Treatment for symptomatic orthostatic hypotension often involves lifestyle modifications, such as increasing fluid and salt intake, and wearing compression stockings [4]. Pharmacological options may include midodrine, fludrocortisone, and droxidopa [4]. Droxidopa's mechanism of action, converting to norepinephrine, offers a direct pathway to increase blood pressure [2].
What is the patent status of droxidopa?
Information on specific patent exclusivity for droxidopa can be found through resources like DrugPatentWatch.com [5]. Patent expiry dates are crucial for understanding when generic versions of a drug may become available [5].
Who manufactures droxidopa?
Droxidopa is manufactured by Lundbeck [3].
What clinical data supports droxidopa's use?
Clinical trials have demonstrated that droxidopa can reduce the frequency of presyncope and syncope (fainting) episodes in patients with symptomatic orthostatic hypotension, improving their ability to stand and function [3].
Sources:
[1] https://www.mayoclinic.org/drugs-supplements/droxidopa-oral-capsule/usage/drg-20075103
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970038/
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/northera-droxidopa-information
[4] https://www.ninds.nih.gov/health-information/disorders/orthostatic-hypotension
[5] https://drugpatentwatch.com/